{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:11:04Z","timestamp":1791198664382,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":2604,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.bbadis.2006.03.004","type":"journal-article","created":{"date-parts":[[2006,4,18]],"date-time":"2006-04-18T19:19:35Z","timestamp":1145387975000},"page":"616-626","source":"Crossref","is-referenced-by-count":105,"title":["Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice"],"prefix":"10.1016","volume":"1762","author":[{"given":"Karen M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Matson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne R.","family":"Matson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Del Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean W.","family":"Hagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbadis.2006.03.004_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20624","article-title":"Mitochondria take center stage in aging and neurodegeneration","volume":"58","author":"Beal","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib2","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2006.03.004_bib3","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2006.03.004_bib4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2006.03.004_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","article-title":"Experimental therapeutics in transgenic mouse models of Huntington's Disease","volume":"5","author":"Beal","year":"2004","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.bbadis.2006.03.004_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2006.03.004_bib7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.expneurol.2004.05.003","article-title":"Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease","volume":"188","author":"Shults","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","article-title":"Tolerance of high-dose (3000\u00a0mg\/day) coenzyme Q10 in ALS","volume":"65","author":"Ferrante","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2006.03.004_bib10","first-page":"109","article-title":"Relative bioavailability of coenzyme Q10 formulations in human subjects","volume":"68","author":"Chopra","year":"1998","journal-title":"Int. J. Vitam. Nutr. Res."},{"issue":"1203","key":"10.1016\/j.bbadis.2006.03.004_bib11","first-page":"U1108","article-title":"The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly","volume":"117","author":"Molyneux","year":"2004","journal-title":"N. Z. Med. J."},{"issue":"4","key":"10.1016\/j.bbadis.2006.03.004_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cne.20680","article-title":"Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington's disease transgenic mice","volume":"490","author":"Stack","year":"2005","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/j.bbadis.2006.03.004_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1602\/neurorx.1.3.298","article-title":"Translating therapies for Huntington's disease from genetic animal models to clinical trials","volume":"1","author":"Hersch","year":"2004","journal-title":"NeuroRx"},{"issue":"2","key":"10.1016\/j.bbadis.2006.03.004_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/14728214.10.2.345","article-title":"Emerging chemotherapeutic strategies for Huntington's disease","volume":"10","author":"Ryu","year":"2005","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bbadis.2006.03.004_bib15","series-title":"Abstract Viewer\/Itinerary Planner","article-title":"Therapeutic effects of high dose administration of coenzyme Q10 in the R6\/2 model of Huntington's disease","author":"Smith","year":"2004"},{"key":"10.1016\/j.bbadis.2006.03.004_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2006.03.004_bib17","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2006.03.004_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1471-4159.2004.02726.x","article-title":"Anti-oxidant activity of cystamine: relevance to therapy for Huntington's disease","volume":"91","author":"Fox","year":"2004","journal-title":"J. Neurochem."},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2006.03.004_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2004.12.011","article-title":"Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6\/2 mouse model of Huntington's disease","volume":"231","author":"Wang","year":"2005","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2006.03.004_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2006.03.004_bib21","first-page":"311","article-title":"Antioxidative effect of dietary coenzyme Q10 in human blood plasma","volume":"64","author":"Weber","year":"1994","journal-title":"Int. J. Vitam. Nutr. Res."},{"issue":"5\u20136","key":"10.1016\/j.bbadis.2006.03.004_bib22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0891-5849(99)00113-6","article-title":"A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2\u2032-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods","volume":"27","author":"Bogdanov","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbadis.2006.03.004_bib23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1046\/j.1471-4159.2001.00689.x","article-title":"Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease","volume":"79","author":"Bogdanov","year":"2001","journal-title":"J. Neurochem."},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2006.03.004_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cccn.2003.12.002","article-title":"Measurement of reduced and oxidized coenzyme Q9 and coenzyme Q10 levels in mouse tissues by HPLC with coulometric detection","volume":"341","author":"Tang","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbadis.2006.03.004_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1139\/o92-061","article-title":"An analysis of the role of coenzyme Q in free radical generation and as an antioxidant","volume":"70","author":"Beyer","year":"1992","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/10715769409145637","article-title":"Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria","volume":"20","author":"Noack","year":"1994","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bbadis.2006.03.004_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(90)91971-T","article-title":"Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling","volume":"169","author":"Kagan","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2006.03.004_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/415096a","article-title":"Superoxide activates mitochondrial uncoupling proteins","volume":"415","author":"Echtay","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2006.03.004_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1212\/WNL.39.3.399","article-title":"Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: A31P NMR study","volume":"39","author":"Nishikawa","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2006.03.004_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0022-510X(89)90112-3","article-title":"Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone","volume":"90","author":"Ihara","year":"1989","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbadis.2006.03.004_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s004150050267","article-title":"Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy","volume":"245","author":"Chan","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0891-5849(99)00132-X","article-title":"Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes","volume":"27","author":"Tomasetti","year":"1999","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.bbadis.2006.03.004_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.57.3.515","article-title":"Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency","volume":"57","author":"Di Giovanni","year":"2001","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.bbadis.2006.03.004_bib34","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2174\/0929867033456882","article-title":"Coenzyme Q10 in neurodegenerative diseases","volume":"10","author":"Shults","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbadis.2006.03.004_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0076-6879(04)82026-3","article-title":"Therapeutic effects of coenzyme Q10 in neurodegenerative diseases","volume":"382","author":"Beal","year":"2004","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-7091-0579-5_13","article-title":"Coenzyme Q10 serum levels in Huntington's disease","volume":"68","author":"Andrich","year":"2004","journal-title":"J. Neural Transm., Suppl."},{"issue":"3","key":"10.1016\/j.bbadis.2006.03.004_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.bbadis.2006.03.004_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.mcn.2003.11.014","article-title":"Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease","volume":"25","author":"Zeron","year":"2004","journal-title":"Mol. Cell. Neurosci."},{"issue":"7","key":"10.1016\/j.bbadis.2006.03.004_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbadis.2006.03.004_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ana.21891","article-title":"Minocycline is protective in a mouse model of Huntington's disease","volume":"54","author":"Hersch","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2006.03.004_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"18","author":"Steffan","year":"2001","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.bbadis.2006.03.004_bib42","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.bbadis.2006.03.004_bib43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2006.03.004_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington's disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol."},{"issue":"1","key":"10.1016\/j.bbadis.2006.03.004_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(99)00578-9","article-title":"Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex","volume":"272","author":"Polidori","year":"1999","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.bbadis.2006.03.004_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington's disease is safe, tolerable, and bioavailable in brain and reduces serum 8-OHDG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2006.03.004_bib47","unstructured":"United States Department of Health and Human Services, Federal Drug Administration, Guidance for industry and reviewers estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, (2003) http:\/\/www.fda.gov\/cber\/guidelines.htm."},{"key":"10.1016\/j.bbadis.2006.03.004_bib48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2006.03.004_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/01.WNL.0000070186.97463.A7","article-title":"Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study","volume":"61","author":"Tabrizi","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.bbadis.2006.03.004_bib50","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"NEALS Consortium, A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bbadis.2006.03.004_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrd987","article-title":"Knockouts model the 100 best-selling drugs\u2014will they model the next 100?","volume":"2","author":"Zambrowicz","year":"2003","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443906000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443906000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T02:31:41Z","timestamp":1555554701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443906000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0925443906000482"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2006.03.004","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}